Form 424B5 Relmada Therapeutics Inc For: 30 January
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Relmada Therapeutics Inc (RLMD)
Relmada Therapeutics Inc stock price live, this page displays NASDAQ RLMD stock exchange data. View the RLMD premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Relmada Therapeutics Inc real time stock price chart below.
What Is the Relmada Therapeutics Inc Stock Price Today?
The Relmada Therapeutics Inc stock price today is 4.200.
What Is the Stock Symbol for Relmada Therapeutics Inc?
The stock symbol for Relmada Therapeutics Inc is ""RLMD.""
What Stock Exchange Does Relmada Therapeutics Inc Trade On?
Relmada Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Relmada Therapeutics Inc a Good Stock to Buy?
Determining whether Relmada Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RLMD quote. (ISIN: US75955J4022)
What Is the Relmada Therapeutics Inc Stock Price Today?
The Relmada Therapeutics Inc stock price today is 4.200.
What Is the Stock Symbol for Relmada Therapeutics Inc?
The stock symbol for Relmada Therapeutics Inc is ""RLMD.""
What Stock Exchange Does Relmada Therapeutics Inc Trade On?
Relmada Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Relmada Therapeutics Inc a Good Stock to Buy?
Determining whether Relmada Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RLMD quote. (ISIN: US75955J4022)
Fair Value
An estimate of a Relmada Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.780
4.346
52 wk Range
0.240
5.120
RLMD is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Relmada Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.7804.346
52 wk Range
0.2405.120
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockRLMD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Relmada Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
9.000
Upside
+114.29%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Relmada Therapeutics Inc Company Profile
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Relmada Therapeutics Inc Earnings Call Summary for Q3/2025
- Relmada Therapeutics reported Q3 2025 EPS of -$0.30, beating forecasts of -$0.45 by 33.33%, though shares fell 3.32% in premarket trading to $3.78.
- Cost-cutting measures significantly reduced R&D expenses to $4M (from $11.1M) and G&A expenses to $6.3M (from $11.9M) compared to Q3 2024.
- The company reported strong clinical trial results for NDV-01 with a 92% response rate, with Phase 3 studies set to begin in H1 2026.
- Relmada raised $100M in November 2025, extending its operational runway through 2028, with cash and equivalents at $13.9M as of September 30.
- Management anticipates first patient data by Q4 2026 and top-line results by Q2 2028, with potential NDV-01 pricing ranging from $120,000 to $700,000 annually.
Last Updated: 13/11/2025, 23:30
Read Full TranscriptCompare RLMD to Peers and Sector
Metrics to compare | RLMD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRLMDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.5x | −2.3x | −0.5x | |
PEG Ratio | −0.15 | −0.09 | 0.00 | |
Price/Book | 32.5x | 2.0x | 2.6x | |
Price / LTM Sales | - | 2.6x | 3.3x | |
Upside (Analyst Target) | 110.3% | 257.7% | 45.0% | |
Fair Value Upside | Unlock | 30.3% | 5.1% | Unlock |
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 9.000
(+114.29% Upside)
Earnings
Latest Release
Nov 13, 2025
EPS / Forecast
-0.30 / -0.45
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Relmada Therapeutics (RLMD) Premarket Price Today?
The Relmada Therapeutics (RLMD) premarket price is 3.930. Premarket price change units: 0.050. Premarket percentage change: 1.290%. Premarket volume: 9,010.000. Current date: 10 Feb 2026. Previous close: 3.880
What Is the Stock Symbol for Relmada Therapeutics?
The stock symbol for Relmada Therapeutics is "RLMD."
What Is the Relmada Therapeutics (RLMD) Afterhours Price Today? (Afterhours variable test: 4.160) Current Date: 10 Feb 2026
After hours price: 4.160. After hours price change (units): -0.040. Price change percentage: -0.950%
What Is the Relmada Therapeutics Market Cap?
As of today, Relmada Therapeutics market cap is 310.93M.
What Is Relmada Therapeutics's Earnings Per Share (TTM)?
The Relmada Therapeutics EPS (TTM) is -1.77.
When Is the Next Relmada Therapeutics Earnings Date?
Relmada Therapeutics will release its next earnings report on 23 Mar 2026.
From a Technical Analysis Perspective, Is RLMD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Relmada Therapeutics Stock Split?
Relmada Therapeutics has split 2 times.
How Many Employees Does Relmada Therapeutics Have?
Relmada Therapeutics has 17 employees.
What is the current trading status of Relmada Therapeutics (RLMD)?
As of 10 Feb 2026, Relmada Therapeutics (RLMD) is trading at a price of 4.200, with a previous close of 3.880. The stock has fluctuated within a day range of 3.780 to 4.346, while its 52-week range spans from 0.240 to 5.120.
What Is Relmada Therapeutics (RLMD) Price Target According to Analysts?
The average 12-month price target for Relmada Therapeutics is USD9.000, with a high estimate of USD10 and a low estimate of USD8. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +114.29% Upside potential.
What Is the RLMD Premarket Price?
RLMD's last pre-market stock price is 3.930. The pre-market share volume is 9,010.000, and the stock has decreased by 0.050, or 1.290%.
What Is the RLMD After Hours Price?
RLMD's last after hours stock price is 4.160, the stock has decreased by -0.040, or -0.950%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.